GC Green Cross has restructured its research and development (R&D) strategy to focus on five key pipelines, expanding its growth strategy from plasma-derived products and vaccines into new areas such as anticancer treatments.
On June 25, the company announced that it has redefined its priority pipelines during its 2026 R&D portfolio review workshop, aiming to drive future growth.
The five core assets, referred to as 'THE FAB FIVE,' include: △20% SCIG (GC5136B) △mCOVID vaccine (GC4006A) △EBV subunit vaccine (GC1140B) △Fabry disease treatment (GC1134A) △EGFR X cMET ADC (GC1148A). This selection maintains the company's strengths in plasma-derived products and vaccines while also expanding into the oncology sector.
In the first quarter of this year, the company's performance was led by Aliglo. GC Green Cross also reported stable operations in its vaccine and rare disease treatment pipelines, reinforcing its foundation in immunology-focused early projects. Additionally, the company has established an internal system to continuously prioritize its pipelines.
Jae-wook Jeong, head of R&D at GC Green Cross, stated, "We will concentrate our R&D capabilities and strategic investments around our core pipelines to strengthen our growth momentum."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.